The clinical trial is the first to demonstrate the activity of a JAK inhibitor in the treatment of myeloma patients.
The phase 1b/2 trial will begin enrollment in the second half of 2018.
This case highlights the appropriate use of genetic testing and supports expanding the clinical diagnosis of multiple endocrine neoplasia type 1...
New analytic tools and data use genetic signatures to help researchers distinguish the differences among various cancers.
New findings support the idea of changing treatment for adverse effects of chemotherapy to a treatment for fighting the cancer.
A pediatric patient developed a secondary T-cell lymphoma during a phase 1 trial of tazemetostat.
The poor prognosis of mantle cell lymphoma despite advances in immunochemotherapy means that new therapeutic targets are needed.
Advances in genomics, diagnostics and therapies since 2008 are reflected in the guidelines.
Making the right diagnosis when radiologic evidence is misleading.
The approval is based on results from the ECHELON-1 trial in previously untreated patients with stage III or IV classical Hodgkin lymphoma.